Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences Limited
Woman and Man Max 99 years
Gilead Sciences Limited
Update Il y a 4 ans
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raised Cholesterol
To determine if switching from a stable HAART regimen of Kivexa + EFV to once daily Atripla leads to a reduction in total fasting cholesterol at 12 weeks.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences Limited
Update Il y a 4 ans
A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir DF) on an Empty Stomach
To evaluate pure virological response rates (defined as subjects who do not have pure virologic failure at HIV-1 RNA threshold of 50 copies/mL) in antiretroviral-experienced subjects receiving Atripla...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences Limited
Update Il y a 4 ans
A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz
To determine if switching from Combivir® or AZT +3TC to a fixed-dose tablet of FTC/TDF leads to changes in absolute haemoglobin at 24 weeks.
Country
None
organs
None
Specialty
None
unknown
More information